FDA-cleared profile

ProFound Detection (V4.0)

iCAD, Inc. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.

Clinical role
Concurrent detection, localization, and characterization aid; physician review and confirmation or dismissal remain required.
Images and patients
Mammography/DBT · Breast.
Key limitation
Keep in mind: Concurrent adjunctive use with compatible DBT systems is required; interpreting physicians confirm or dismiss marked findings. Certainty of Finding and Case Scores are algorithm confidence scores, and the packet does not establish them as calibrated probabilities or a replacement for physician review.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast. Input: 3D DBT exams from compatible DBT systems; prior exams may be processed when available. The standalone test used Hologic DBT exams, and the submission lists Hologic, GE, and Siemens compatible systems under its supported-system/PCCP discussion.
  • Who uses it?Intended users: Interpreting physicians.
  • What does the software produce?Output: Overlay marks on tomosynthesis images, a maximum of three marks per view, Certainty of Finding scores from 0%-100% for detected findings, Case Scores from 0%-100% for cases, and softcopy-workstation display; prior-exam processing is supported when available.
  • What is its most important limitation?Key limitation: Concurrent adjunctive use with compatible DBT systems is required; interpreting physicians confirm or dismiss marked findings. Certainty of Finding and Case Scores are algorithm confidence scores, and the packet does not establish them as calibrated probabilities or a replacement for physician review.

Clinical takeaway. Clinical role: Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.

Evidence takeaway. Evidence from the reviewed source record: FDA K240417 reports a primary non-inferiority/paired comparison and standalone performance results in the same independent-data discussion. The standalone dataset contains 952 cases, including 251 biopsy-proven cancer cases with 256 malignant lesions and 701 non-cancer cases. V4.0 using priors reported sensitivity 0.9004, specificity 0.6205, and AUC 0.8753; V4.0 without priors reported 0.9004, 0.5863, and 0.8714; the predicate V3.0 reported 0.8725, 0.5278, and 0.8230. The data were retrospectively collected from U.S. image-acquisition sites and used established clinical reference standards.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Concurrent detection, localization, and characterization aid; physician review and confirmation or dismissal remain required.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
3D DBT exams from compatible DBT systems; prior exams may be processed when available. The standalone test used Hologic DBT exams, and the submission lists Hologic, GE, and Siemens compatible systems under its supported-system/PCCP discussion.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Overlay marks on tomosynthesis images, a maximum of three marks per view, Certainty of Finding scores from 0%-100% for detected findings, Case Scores from 0%-100% for cases, and softcopy-workstation display; prior-exam processing is supported when available.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Breast-imaging and DBT reading workflow using compatible DBT acquisition systems; the FDA packet does not specify a facility type or an intended age range.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Concurrent adjunctive use with compatible DBT systems is required; interpreting physicians confirm or dismiss marked findings. Certainty of Finding and Case Scores are algorithm confidence scores, and the packet does not establish them as calibrated probabilities or a replacement for physician review.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K240417 reports a primary non-inferiority/paired comparison and standalone performance results in the same independent-data discussion. The standalone dataset contains 952 cases, including 251 biopsy-proven cancer cases with 256 malignant lesions and 701 non-cancer cases. V4.0 using priors reported sensitivity 0.9004, specificity 0.6205, and AUC 0.8753; V4.0 without priors reported 0.9004, 0.5863, and 0.8714; the predicate V3.0 reported 0.8725, 0.5278, and 0.8230. The data were retrospectively collected from U.S. image-acquisition sites and used established clinical reference standards.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K240417 reports a primary non-inferiority/paired comparison and standalone performance results in the same independent-data discussion. The standalone dataset contains 952 cases, including 251 biopsy-proven cancer cases with 256 malignant lesions and 701 non-cancer cases. V4.0 using priors reported sensitivity 0.9004, specificity 0.6205, and AUC 0.8753; V4.0 without priors reported 0.9004, 0.5863, and 0.8714; the predicate V3.0 reported 0.8725, 0.5278, and 0.8230. The data were retrospectively collected from U.S. image-acquisition sites and used established clinical reference standards.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

ProFound Detection (V4.0) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240417
  • Samplen=952
  • IndependenceIndependence not established

K240417

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240417. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: 3D DBT exams from compatible DBT systems; prior exams may be processed when available. The standalone test used Hologic DBT exams, and the submission lists Hologic, GE, and Siemens compatible systems under its supported-system/PCCP discussion.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K240417: ProFound Detection (V4.0)

  2. Routing

    Source context, not route validation: Softcopy-workstation display with compatible DBT acquisition systems is described, including a predetermined change-control plan for additional systems. A specific PACS, RIS, EHR, or routing interface is not established by the packet.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240417: ProFound Detection (V4.0)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Overlay marks on tomosynthesis images, a maximum of three marks per view, Certainty of Finding scores from 0%-100% for detected findings, Case Scores from 0%-100% for cases, and softcopy-workstation display; prior-exam processing is supported when available.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K240417: ProFound Detection (V4.0)

  5. Viewer/worklist/report

    Unresolved route: Overlay marks on tomosynthesis images, a maximum of three marks per view, Certainty of Finding scores from 0%-100% for detected findings, Case Scores from 0%-100% for cases, and softcopy-workstation display; prior-exam processing is supported when available.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K240417: ProFound Detection (V4.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Softcopy-workstation display with compatible DBT acquisition systems is described, including a predetermined change-control plan for additional systems. A specific PACS, RIS, EHR, or routing interface is not established by the packet.
  • Exact FDA submission
  • Checked 2026-09-08
Security
iCAD's coordinated vulnerability disclosure statement commits to vulnerability intake via support@icadmed.com, confidential report handling, an evaluation response with an expected resolution date based on severity, progress updates to the reporter, and a safe-harbor commitment not to take legal action against reporters who follow the policy.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement on the iCAD owning domain (icadmed.com); the page banner notes iCAD is now part of DeepHealth, but the statement is iCAD's own product/system disclosure policy. No certification or audit report was read; exact-release scope is not established. Applicant name variant 'iCAD, Inc.' is bridged to iCAD, Inc. via the identical distinctive name and iCAD product naming.

Monitoring
iCAD's coordinated vulnerability disclosure statement states confidential intake, an evaluation response with a severity-based expected resolution date, and progress updates to the reporter.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The statement names iCAD generally and does not scope these commitments to any specific product release; exact-release scope is not established.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for ProFound Detection (V4.0); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240417
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Breast.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-11-08
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240417 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K240417: ProFound Detection (V4.0)

    U.S. Food and Drug Administration - Published 2024-11-08 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ProFound Detection (V4.0) model card (K240417)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240417

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. iCAD: Coordinated Vulnerability Disclosure Statement

    iCAD - Accessed 2026-10-27

    Scope: security

Research history

  1. K240417 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23
FDA-cleared K253796

Lunit INSIGHT DBT (V1.2)

Lunit, Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-03-26
FDA-cleared K243341

Genius AI Detection 2.0

Hologic, Inc.

Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-07-31

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history